A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Glaxo Wellcome
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have:
HIV infection with CD4 counts = or \> 100 cells/mm3.
Documented culture of anogenital herpes simplex virus (HSV) within the last 5 years.
History of recurrent anogenital HSV infection, with a recurrence (with or without culture) within 1 year prior to study.
You may not be if
Co-existing Condition:
Patients with the following symptoms and conditions are excluded:
Malabsorption or vomiting that would potentially limit the retention and absorption of oral therapy.
Concurrent Medication:
Excluded:
Systemic antiherpes medication.
Interferon.
Patients with the following prior conditions are excluded:
History of hypersensitivity to acyclovir.
Clareo Health | A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients
